U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H23N3O
Molecular Weight 225.3305
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ESAPRAZOLE

SMILES

O=C(CN1CCNCC1)NC2CCCCC2

InChI

InChIKey=RTFADALJKSFJDZ-UHFFFAOYSA-N
InChI=1S/C12H23N3O/c16-12(10-15-8-6-13-7-9-15)14-11-4-2-1-3-5-11/h11,13H,1-10H2,(H,14,16)

HIDE SMILES / InChI

Molecular Formula C12H23N3O
Molecular Weight 225.3305
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Esaprazole, also known as hexaprazole, was developed in the 1980s as a drug for the treatment of gastric and duodenal ulcers. Esaprazole exerts a dose-dependent cytoprotective effect on the gastric mucosa in man. It was shown to have a dose-dependent antisecretory activity, which was particularly evident on secretion volume and acid output. Esaprazole completed phase II clinical trials with only a few minor side effects being reported, but was shown to be less effective than Cimetidine and Ranitidine at healing ulcers. Esaprazole is a weak sigma opioid receptor and muscarinic acetylcholine receptors M3 and M5 ligand. Esaprazole analogs with many compounds showing neuroprotective properties.

CNS Activity

Curator's Comment: low brain penetration potential

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
27.0 µM [IC50]
Target ID: P08483
Gene ID: 24260.0
Gene Symbol: Chrm3
Target Organism: Rattus norvegicus (Rat)
87.0 µM [IC50]
71.0 µM [IC50]
Conditions
Doses

Doses

DosePopulationAdverse events​
1350 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1350 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1350 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Condition: gastric ulcer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
900 mg single, intravenous
Highest studied dose
Dose: 900 mg
Route: intravenous
Route: single
Dose: 900 mg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: gastrointestinal disorder
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Inhibitory cholinergic effects of esaprazole on gastric secretion and plasma gastrin levels in the dog.
1993 Apr
[Bis(3,5-dimethyl-pyrazol-1-yl)methane]{N-[1-(2-oxidophen-yl)ethyl-idene]-dl-alaninato}copper(II) monohydrate.
2008 Nov 13
Effects of positive allosteric modulators on single-cell oscillatory Ca2+ signaling initiated by the type 5 metabotropic glutamate receptor.
2009 Dec
Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia.
2011 May
Synthesis and biological evaluation of Esaprazole analogues showing σ1 binding and neuroprotective properties in vitro.
2013 Jun 1
Patents

Sample Use Guides

Once a day at doses of 900 and 1350 mg/day
Route of Administration: Oral
Esaprazole prevented cell death in a dose-dependent manner against both glutamate and peroxide-induced cell death in primary culture of cortical neurons, with a 27% and 44% decrease in cell death at concentration 100 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:20:21 GMT 2023
Edited
by admin
on Fri Dec 15 16:20:21 GMT 2023
Record UNII
38QSU0IB5L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ESAPRAZOLE
INN   MI  
INN  
Official Name English
N-CYCLOHEXYL-1-PIPERAZINEACETAMIDE
Systematic Name English
ESAPRAZOLE [MI]
Common Name English
C-63
Code English
1-PIPERAZINYL-4-METHYLENECARBONYLCYCLOHEXYLAMINE
Common Name English
1-PIPERAZINEACETAMIDE, N-CYCLOHEXYL-
Systematic Name English
esaprazole [INN]
Common Name English
EXAPRAZOLE
Common Name English
N-(1-PIPERAZINYLACETYL)CYCLOHEXYLAMINE
Common Name English
HEXAPRAZOLE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29701
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
Code System Code Type Description
INN
4975
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
PUBCHEM
68835
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
EVMPD
SUB06607MIG
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
FDA UNII
38QSU0IB5L
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
ChEMBL
CHEMBL1983100
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
NCI_THESAURUS
C65535
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
MERCK INDEX
m1136
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY Merck Index
MESH
C042123
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
SMS_ID
100000084583
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
EPA CompTox
DTXSID0046147
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
CAS
64204-55-3
Created by admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY